Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.ajo.2010.08.027
Title: Descemet stripping automated endothelial keratoplasty with a graft insertion device: Surgical technique and early clinical results
Authors: Khor, W.-B.
Mehta, J.S. 
Tan, D.T.-H.
Issue Date: Feb-2011
Citation: Khor, W.-B., Mehta, J.S., Tan, D.T.-H. (2011-02). Descemet stripping automated endothelial keratoplasty with a graft insertion device: Surgical technique and early clinical results. American Journal of Ophthalmology 151 (2) : 223-232.e2. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ajo.2010.08.027
Abstract: Purpose To present the surgical technique and the early clinical results of the EndoGlide, a graft insertion device for use during Descemet stripping automated endothelial keratoplasty (DSAEK). Design Prospective interventional case series. Methods patients: Graft insertion with the EndoGlide was performed in 25 eyes of Asian patients with endothelial dysfunction suitable for DSAEK. Demographic and clinical details, best-corrected visual acuity, postoperative complications, and endothelial cell density (ECD) loss were documented. surgical technique: The prepared graft is transferred onto a preparation base and pulled into the glide capsule with forceps. Drawing the graft into the capsule curls it into a "double-coil" configuration. The assembled EndoGlide is inserted into the eye, and the graft is pulled into the anterior chamber with forceps, where it uncoils in the correct orientation with minimal manipulation. Results Average age was 70 years (range 28-91) and the commonest diagnosis was pseudophakic bullous keratopathy (12 eyes). Preoperative donor ECD was 2957 ± 242 cells/mm2, median graft diameter was 8.75 mm, and all surgeries were completed successfully by 2 surgeons. There was a short learning curve in loading of the graft into the EndoGlide and in uncoiling the graft in the recipient eye. No patient had graft dislocation or primary iatrogenic graft failure. At 6 months, the mean ECD was 2586 ± 338 cells/mm2 and mean cell loss was 13.1% in 20 eyes. At 12 months, the mean ECD was 2575 ± 289 cells/mm2 and mean cell loss was 15.6% in 10 eyes. Conclusions Graft insertion with the EndoGlide is safe in DSAEK, with a short learning curve and a low endothelial cell loss at 6 and 12 months. © 2011 Elsevier Inc.
Source Title: American Journal of Ophthalmology
URI: http://scholarbank.nus.edu.sg/handle/10635/110016
ISSN: 00029394
DOI: 10.1016/j.ajo.2010.08.027
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.